

## Gene expression profile association with poor prognosis in epithelial ovarian cancer patients

Douglas V.N.P. Oliveira <sup>1</sup>, Kira P. Prahm <sup>1</sup>, Ib J. Christensen<sup>1</sup>, Anker Hansen<sup>3</sup>, Claus K. Høgdall <sup>2</sup>,  
Estrid V. Høgdall <sup>1,\*</sup>

<sup>1</sup> Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark

<sup>2</sup> Department of Gynaecology, Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

<sup>3</sup> Oncology Venture, Denmark

\* corresponding author: [estrid.hoegdall@regionh.dk](mailto:estrid.hoegdall@regionh.dk)

Key words: global mRNA profiling, biomarker, ovarian cancer.

Running title: Global mRNA profile in epithelial ovarian cancer.

## Supplementary information

Supplementary Table S1

Supplementary Figure S1

Supplementary Figure S2

Supplementary Figure S3

Supplementary Figure S4

Supplementary Figure S5

Supplementary Figure S6





Supplementary Figure S7

Supplementary Figure S8

Histologic subtype	HSPA1A		CD99		RAB3A		POM121L9P	
	Median	Std.Dev.	Median	Std.Dev.	Median	Std.Dev.	Median	Std.Dev.
Clear Cell	9.456	0.812	9.348	0.611	5.789	0.292	3.364	0.437
Endometrioid	9.121	0.576	9.248	1.049	5.718	0.420	3.153	0.461
Mucinous	9.668	0.629	9.188	0.268	5.781	0.431	3.498	0.389
Serous	9.933	0.724	8.949	0.623	5.929	0.427	3.284	0.714


**Supplementary Table S1.** Median expression values of *HSPA1A*, *CD99*, *RAB3A* and *POM121L9P* in each histologic subtype. Std.Dev.= standard deviation.

## Supplementary Figure S1




**Supplementary Figure S1.** Gene expression in “low risk” (blue) and “high risk” (orange) groups. Values are normalized and provided as log2 and P-value is presented above.

## Supplementary Figure S2




**Supplementary Figure S2.** Overall survival curves for each candidate (*HSPA1A*, *CD99*, *RAB3A* and *POM121L9P*) individually in “high risk” (red) and “low risk” (blue) groups (a-d). (e)ROC/AUC for *RAB3A* alone for 60 months patient OS. P-values are presented above.

### Supplementary Figure S3



**Supplementary Figure S3.** (a) Survival curve between “high risk” (red) and “low risk” (blue) in serous adenocarcinoma subtype. (b) Survival curve between serous adenocarcinoma and other OC subtypes. (c) AUC/ROC curve of combination of HSPA1A, CD99, RAB3A and POM121L9P in serous adenocarcinoma x other OC subtypes. P-values and AUC are presented above.


## Supplementary Figure S4



**Supplementary Figure S4.** Gene expression in all OC subtypes for *HSPA1A* (a), *CD99* (b), *RAB3A* (c) and *POM121L9P* (d). Values are normalized and provided as log2 and P-values are presented above.

## Supplementary Figure S5

**a**




**Supplementary Figure S5.** Survival curve between “high risk” (red) and “low risk” (blue) in high grade serous adenocarcinoma subtype. P-value is presented above.




## Supplementary Figure S6

**a**




**b**



**Supplementary Figure S6.** (a) Progression-free survival curve between “high risk” (red) and “low risk” (blue) in serous adenocarcinoma subtype. (b) Progression-free survival curve between serous adenocarcinoma and other OC subtypes. P-values are presented above.


# Supplementary Figure S7




**Supplementary Figure S7.** Validation study. (a) Survival curve shows that “high risk” (all candidates overexpressed) group has a shorter survival compared to “low risk” OC patients, and (b) AUC/ROC curve of combination of HSPA1A, CD99, RAB3A and POM121L9P for 5-year OS in cohort GSE26193 ( $n = 107$ ). The 97-gene signature performance from Matondo *et al.* (2017) in our current cohort ( $n = 196$ ) showing (c) Heatmap and classification of “high-” (red) and “low risk” (high) groups. (d) K-M curve for the “high-” and “low risk” groups, and table with median OS of patients on both cohorts and both signature panels. P-values and AUC are presented above.

## Supplementary Figure S8

a



b



**Supplementary Figure S8.** Assessment of the 97-gene signature panel from Matondo and colleagues on cohort GSE26193 (n= 107). (a) Survival curve shows that “high risk” group has a shorter survival compared to “low risk” OC patients. (b) Heatmap and classification of “high-” (red) and “low risk” (high) groups. P-value is presented above.